United States Pharmaceuticals and Healthcare Report Q3 2012 - new market research report published

companiesandmarkets.com

2012-07-30 01:12:25 - United States Pharmaceuticals and Healthcare Report Q3 2012 - a new market research report on companiesandmarkets.com

The price of this market report covers 4 quarterly reports on this sector. This quarterly report will be downloadable instantly as a PDF document, with the 3 remaining reports delivered at regular intervals throughout the year.The US pharmaceutical market is entering a period of relative stagnation. Patent expiries, fewer insured patients and greater use of rebates and discounts are creating

 

 

severe headwinds to growth.

A major downside risk is reduced tolerance for medicine price increases from payers, both public and private. We stress, however, that the US pharmaceutical market is still the most attractive globally, due to its large size and rapid uptake of newly approved innovative, and therefore high-priced, medicines.

Headline Expenditure Projections

- Pharmaceuticals: US$337.1bn in 2011 to US$343.1bn in 2012; +1.8% growth in local currency terms. Market size increased since Q212 due to new historic data, resulting in an upgraded forecast.

- Healthcare: US$2,708bn in 2011 to US$2,864bn in 2011; +5.8% growth in local currency terms. Market size increased since Q212 due to new historic data, resulting in an upgraded forecast.

- Medical devices: US$133bn in 2010 to US$139bn in 2011; +4.4% growth in local currency terms. Forecast is up slightly from Q212 due to new historic data.

Risk/Reward Ratings

The US Pharmaceutical Risk/Reward Rating (RRR) for Q312 is 79.1 out of 100, which is unchanged from the previous quarter. The country scores well above average for all indicators, except market growth, which is in the low single-digits. Key attributes include transparent regulations, an ageing population and a stable economic/political framework.

Key Trends And Developments

- In May 2012, BMI switched its primary data provider for US OTC medicine sales from the Association of the European Self-Medication Industry (AESGP) to the Consumer Healthcare Products Association (CHPA), which provides more reliable numbers over a longer time frame.

- In May 2012, Swiss pharmaceuticals firm Novartis acquired US dermatology specialist Fougera. The acquisition reportedly cost Novartis US$1.525bn and will allow it to emerge as a global leader in the production of generic dermatology treatments.

- In April 2012, a ruling by the US Supreme Court allowed generic drug manufacturers to challenge attempts from pharmaceutical firms to extend the remit of existing patent descriptions. The ruling overrides a decision by the court of appeals in 2010. It follows Novo Nordisk´s efforts to amend the phrasing of a patent covering its Prandin (repaglinide) drug.

- In April 2012, BMI revised upwards its forecast for the US pharmaceutical market, following the receipt of newly released historic data. We now expect combined sales of prescription drugs and over-the-counter medicines to increase from US$337bn in 2011 to US$343bn in 2012, equating to 1.8% growth.

The US Food and Drug Administration (FDA) gained the authority to approve biosimilars as part of the Patient Protection and Affordable Care Act (PPAC Act) signed by President Barack Obama on March 23 2010, which is also referred to as the Biologics Price Competition and Innovation Act 2009 (BPCI Act).

BMI Economic View

With the bounce in US growth in the latter part of 2011 set to moderate as 2012 progresses, we are maintaining our 2012 real GDP growth forecast of 2.0%, followed by 2.4% in 2013.

The biggest risks come from abroad, with the European debt and economic crisis representing a constant threat to US economic stability.

BMI Political View

The November 2012 presidential and congressional elections are finely poised. The Republican Party is set to gain ground on the Democratic Party in the Senate, but the presidential race is much tougher to call. The outcome of the elections will be crucial in determining medium-term policy direction. But in the interim we expect continued policy paralysis.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.